Rare CNS Tumors Outcomes &Risk | MicrobiomeTrials← Back to trialsNCT03251989
Rare CNS Tumors Outcomes &Risk
CompletedOBSERVATIONAL
Trial Details
Start: 2017-08-21Est. Completion: 2025-05-06
Enrollment target: 326 participants Locations- National Cancer Institute (NCI)/ Neuro-Oncology Branch, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Neurofibromatosis
Objective
With this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand…
Bethesda, United States
Solid Tumor CancerMedulloblastomaHigh Risk NeuroblastomaHigh Grade GliomasMeningiomaParagangliomaPheochromocytomaNeuroendocrine Tumours (NET)Adrenal Tumours
DIPG
Glioblastoma
Glioblastoma (GBM)
Osteosarcoma Recurrent
Carcinoma Adrenal
Synovial Sarcomas
Esthesioneuroblastoma
Neuroblastoma Recurrent
Solid Tumor Refractory to Conventional Treatment
Medulloblastoma Recurrent
Paraganglioma/ Phaeochromocytoma
Ependymoma
Ependymoma Recurrent
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment…
Boadilla del Monte, SpainEst. completion Jul 2029
Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work…
Birmingham, United StatesEst. completion Jan 1, 2027